MRD testing showed weak trial-level correlation with progression-free survival in BTK inhibitor and venetoclax-based CLL studies.

Andrzej Jakubowiak, MD, PhD, director of the multiple myeloma program at the University of Chicago, discusses the definitive results of the phase 3 ATLAS trial (NCT02659293), recently published in The ...

Safety was described as manageable for both doublet and triplet regimens with no new signals, supporting feasibility of comprehensive pathway targeting in metastatic disease. Company plans include an ...

CHICAGO — The benefit observed with lorlatinib (Lorbrena) in 5-year follow-up data from the CROWN trial corresponds to the longest progression-free survival (PFS) reported for any targeted therapy in ...

Time-of-day immunotherapy may represent a modifiable factor in cancer care, with earlier immune checkpoint inhibitor ...

Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...

Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic lymphocytic leukemia, according to an analysis. The research focused on 2 primary ...

While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.

(NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM ...

Ratios of visceral proteins can act as independent indicators for both overall and progression-free survival in patients with colon cancer. CRC is the second leading cause of cancer deaths worldwide, ...

A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...